Svetlana Makhni was named Chief Financial Officer of Prime Medicine, Inc., effective April 16, 2026. As of November 6, 2026, Prime Medicine, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 16, 2026, naming 1 appointment (Form 8-K, April 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Prime Medicine, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Prime Medicine, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Prime Medicine, Inc. files it.
Also on the record for Prime Medicine, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 3.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 5.3% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Alphabet Holdings LLC | 12.3% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 3.8% of the class | 5%+ stakes | Source |
| August 11, 2025 | Stake report, Schedule 13D/A, by ARCH Venture Fund XII, L.P. | 10.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Prime Medicine, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Prime Medicine, Inc. and the records around it.
Prime Medicine, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Who owns it
Companies that share a holder
- GV 2019, L.P. also filed stake reports on 2 other companies: Ethos Technologies Inc. (Nov 2026), MAZE THERAPEUTICS, INC. (Feb 2026)
- ARCH Venture Fund X, L.P. also filed stake reports on 5 other companies: City Therapeutics, Inc. (Oct 2026), Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Prime Medicine, Inc.
Get an email when Prime Medicine, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Prime Medicine, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Prime Medicine, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Prime Medicine, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-16 | In | Chief Financial Officer | 2026-04-16 | 8-K, 2026-04-16 |
Who leads Prime Medicine, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Svetlana Makhni, appointed, effective 2026-04-16 (filed 2026-04-16).
New leaders reset buying decisions — get the Full Report on Prime Medicine, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Prime Medicine, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Prime Medicine, Inc.Every change, in the filing's words
Appointed: Svetlana Makhni, Chief Financial Officer, effective 2026-04-16
On April 7, 2026, the Board of Directors (the "Board") of Prime Medicine, Inc. (the "Company") appointed Svetlana Makhni as the Chief Financial Officer and the principal financial officer of the Company effective as of April 16, 2026.
- Ms. Makhni, age 42, brings over 20 years of experience across multiple biotechnology and healthcare chief financial officer roles and investment banking.
- Prior to joining the Company, Ms. Makhni served as Chief Financial Officer of Marengo Therapeutics, Inc., a clinical-stage biotechnology company, from June 2022 to April 2026, as Chief Financial Officer of Escient Pharmaceuticals, Inc., a clinical-stage biotechnology company, from May 2021 to June 2022, and as Chief Financial Officer and Head of Operations at Bierman ABA, Inc., a behavioral health services provider, from October 2019 to May 2021.
- From 2006 through 2019, Ms. Makhni worked in investment banking and financial services at BMO Capital Markets, Goldman Sachs, Westbrook Partners and The Blackstone Group, where she advised public and private companies on equity and debt financings, mergers and acquisitions, and other strategic transactions.
- Ms. Makhni received her M.B.A. from Harvard Business School and her B.S. from the Wharton School of the University of Pennsylvania.
- In connection with Ms. Makhni's appointment as Chief Financial Officer, the Company entered into an employment agreement with her (the "Employment Agreement") pursuant to which the Company has agreed to pay Ms. Makhni an annual base salary of $495,000 and a one-time sign-on bonus of $40,000.
Tools for this story
Each opens in a new tab, filled in for Prime Medicine, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.